Clinical Trials Logo

Abortion, Spontaneous clinical trials

View clinical trials related to Abortion, Spontaneous.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06356792 Recruiting - Clinical trials for Recurrent Miscarriage

Obstetrics , Prenatal Outcomes in Recurrent Miscarriage

OBPORPL
Start date: April 21, 2024
Phase:
Study type: Observational

The effect of recurrent miscarriage on the outcome of the current pregnancy and if there's a relation between it and adverse out come

NCT ID: NCT06261203 Recruiting - Pre-Eclampsia Clinical Trials

Low Dose Aspirin for Prevention of Early Pregnancy Loss

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

Preeclampsia is a pregnancy-specific, multisystem disorder affecting 3% to 8% of pregnancies and remains a significant cause of maternal and neonatal morbidity and mortality worldwide. The World Health Organization estimates that approximately 76,000 maternal deaths annually are attributed to preeclampsia, accounting for 16% of global maternal mortality, with the majority occurring in low- and middle-income countries

NCT ID: NCT06121063 Recruiting - Clinical trials for Early Pregnancy Loss, Delayed Pregnancy Loss

CCT-102 vs. Expectant Management in Delayed Pregnancy Loss

MERMAID
Start date: December 15, 2023
Phase: Phase 3
Study type: Interventional

A Phase 3, multi-center clinical trial of a CCT-102 regimen compared to expectant management to promote uterine evacuation in first trimester non-progressing Delayed Pregnancy Loss (DPL).

NCT ID: NCT06007560 Recruiting - Clinical trials for Recurrent Pregnancy Loss

Aerobe Cycling Training in Women With Unexplained Recurrent Pregnancy Loss

HMOVE
Start date: March 21, 2022
Phase: N/A
Study type: Interventional

In 50% of women with recurrent pregnancy loss (RPL) miscarriages are unexplained, therefore no therapeutic intervention is possible. In a pilot study, women with unexplained RPL showed less endometrial NK cells (eNK) compared to women with a previously uncomplicated pregnancy. It is known that eNK cells are important for embryo implantation during early pregnancy. Investigators presume that high sympathetic activity in these women is related to eNK cell number, function and phenotype and that exercise is an effective intervention to lower sympathetic activity and to influence the immune system, as especially peripheral NK cells have been assumed to be responsive to physical training. The investigators hypothesize that moderate exercise can lower the adrenergic tone of the sympathetic nervous system hereby influencing endometrial NK cells in women with RPL and eventually pregnancy outcome.

NCT ID: NCT05989178 Recruiting - Clinical trials for Recurrent Pregnancy Loss

Prospective Recurrent Pregnancy Loss Registry

Start date: July 12, 2022
Phase:
Study type: Observational [Patient Registry]

The purpose of this Registry is to prospectively collect data of Recurrent Pregnancy Loss (RPL) patients attending the specialized care centre at the BC Women's Hospital, in order to evaluate investigation practices, treatment options, and outcomes for this patient population over time.

NCT ID: NCT05969574 Recruiting - Infertility, Female Clinical Trials

Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?

Start date: September 9, 2023
Phase:
Study type: Observational

This study aims to explore the potential correlation between decreased ovarian reserve and previous history of early miscarriage.

NCT ID: NCT05900076 Recruiting - Clinical trials for Spontaneous Miscarriage

Technical Feasibility of the cfDNA Test for Non-invasive Cytogenetic Analysis of Early Miscarriages Versus the Gold Standard Microarray

NICAEA
Start date: July 18, 2023
Phase:
Study type: Observational

Among the 15% of couples who experience a spontaneous early miscarriage (SEM) during their pregnancy, approximately 2 to 5% will suffer from recurrent SEM. It is only after the third SM that they will be offered a workup to look for a predisposition to SEM. This workup does not currently include a search for foetal chromosomal abnormalities that could be considered causal for this event. These anomalies are responsible for approximately 50% of SEM and their detection could lead to an explanation for half of the couples currently without a diagnosis after a standard workup. The diagnosis of chromosomal abnormalities can be made by karyotype analysis or by Cytogenetic Microarray Analysis (CMA) on the product of conception. Unfortunately, karyotyping has a high failure rate due to poor cell culture of samples that are often degraded or of low quantity. The CMA is not always feasible due to the absence of analyzable feto-placental material linked to the use of a drug strategy for its elimination. The study of cell-free DNA of syncytiotrophoblastic origin (cfDNA) circulating in the maternal plasma could be a solution as it is for non-invasive prenatal screening of trisomy 21. cfDNA is detectable from 6 to 8 weeks of amenorrhea and released in the maternal blood as long as placental tissue is present in the uterus, can be easily obtained by maternal venous sampling. If maternal blood sampling is performed before complete removal of the product of conception, then detection of foetal chromosomal abnormalities would be possible. Thus, if failure rates of CMA and cfDNA techniques are comparable, cfDNA could be preferred as it applies for miscarriages for whom no fetoplacental material can be obtained. This study therefore proposes to compare the failure rates of the two technologies (CMA and cfDNA) for the detection of chromosomal abnormalities in recurrent SEM.

NCT ID: NCT05880381 Recruiting - Clinical trials for Early Pregnancy Loss

Virtual Reality for Coping With Involuntary Early Pregnancy Loss

AViR
Start date: May 1, 2023
Phase: N/A
Study type: Interventional

This study aims to provide psychological support to women that experienced an Early Pregnancy Loss (when the loss occurs until the 20 weeks of gestation) using an innovative Virtual Reality prototype and compare the presence and evolution of psychological distress symptoms pre and post-intervention. The main goals of this study are: 1. Evaluate the impact of the proposed VR paradigm in women who suffered a gestational loss in the first 20 weeks of gestation, compared to a control group that follows the usual standard care; 2. Evaluate the usability, user experience, and acceptance of the proposed approach. Participants in the VR group will have an intervention program lasting four weeks, with 3 weekly sessions of 45-60 minutes, using the developed prototype.

NCT ID: NCT05878574 Recruiting - Clinical trials for Recurrent Spontaneous Abortion

Prospective Study of BMD and Ca-P Metabolism in RSA Patients: LMWH Use Versus Control

Start date: November 1, 2022
Phase:
Study type: Observational

The goal of this prospective observational study is to learn about the effect of low molecular weight heparin (LMWH) application on bone mineral density (BMD) and on calcium-phosphorus metabolism in patients with recurrent spontaneous abortion (RSA), and to compare the degree of bone loss and changes in blood calcium and phosphorus in RSA patients and in control groups with normal pregnancy. By monitoring ultrasound BMD and serum indicators related to maternal bone formation and Ca-P metabolism, the association mechanism between long-term use of LMWH, maternal Ca-P regulation and bone loss will be constructed, so as to contribute to clinical treatment and lifestyle guidance during pregnancy in RSA patients.

NCT ID: NCT05824897 Recruiting - Pregnancy Related Clinical Trials

The Cohort Study of the Correlation Between Serum 25(OH)D Level and Pregnancy Outcome

Start date: November 1, 2022
Phase:
Study type: Observational

The objective of this single-center prospective observational study is to clarify the trend of maternal serum 25(OH)D levels before pregnancy and during pregnancy, and to explore the correlation between serum 25(OH)D levels and subsequent pregnancy outcomes of patients with abortion, so as to provide certain scientific evidence for finding the optimal serum level of 25(OH)D and optimal vitamin D supplementation to maintain a healthy pregnancy.